Fulgent Genetics Inc. (NASDAQ:FLGT) previous close was $69.24 while the outstanding shares total 28.83M. The firm has a beta of 1.50, a 12-month trailing P/E ratio of 5.05. FLGT’s shares traded higher over the last trading session, gaining 8.20% on 06/02/21. The shares fell to a low of $68.40 before closing at $74.92. Intraday shares traded counted 1.0 million, which was 26.62% higher than its 30-day average trading volume of 1.36M. The stock’s Relative Strength Index (RSI) is 48.69, with weekly volatility at 6.63% and ATR at 4.60. The FLGT stock’s 52-week price range has touched low of $15.06 and a $189.89 high.
Investors have identified the Diagnostics & Research company Fulgent Genetics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.26 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Fulgent Genetics Inc. (FLGT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For FLGT, the company has in raw cash 151.46 million on their books with 15.05 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 659.14 million total, with 196.53 million as their total liabilities.
FLGT were able to record 221.69 million as free cash flow during the 08/09/2021 quarter of the year, this saw their quarterly net cash flow reduce by 64.03 million. In cash movements, the company had a total of 233.18 million as operating cash flow.
Potential earnings growth for Fulgent Genetics Inc. (FLGT)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/09/2021 quarter of the year, Fulgent Genetics Inc. recorded a total of 359.43 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 97.84% coming in sequential stages and their sales for the 08/09/2021 quarter increasing by 17.93%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 74.08 million trying to sell their products during the last quarter, with the result yielding a gross income of 285.35 million. This allows shareholders to hold on to 28.83M with the recently reported earning now reading 6.96 cents per share. This is a figure that compared to analyst’s prediction for their 08/09/2021 (6.51 cents a share).
Having a look at the company’s valuation, the company is expected to record 4.00 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on FLGT sounds very interesting.
Is the stock of FLGT attractive?
In related news, Chief Operating Officer, Xie Jian sold 647 shares of the company’s stock in a transaction that recorded on May 28. The sale was performed at an average price of 73.46, for a total value of 47,527. As the sale deal closes, the CFO and Treasurer, KIM PAUL now sold 18,000 shares of the company’s stock, valued at 1,312,119. Also, CFO and Treasurer, KIM PAUL sold 10,358 shares of the company’s stock in a deal that was recorded on May 25. The shares were price at an average price of 72.94 per share, with a total market value of 755,479. Following this completion of acquisition, the Chief Operating Officer, Xie Jian now holds 2,000 shares of the company’s stock, valued at 144,412. In the last 6 months, insiders have changed their ownership in shares of company stock by 31.80%.
2 out of 4 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Fulgent Genetics Inc.. 1 analysts has assigned a Sell rating on the FLGT stock. The 12-month mean consensus price target for the company’s shares has been set at $87.00.